At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 61 enrolled
Drug / intervention
ATRIPLAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
In Brief
A Phase 4 clinical trial evaluating ATRIPLA for HIV. Completed, enrolled 61 participants across 1 site.
Detailed Summary
The main objective is to determine the feasibility of maintaining virologic suppression on standard plasma viral load by dose reduction of ATRIPLA ®.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartJun 2013
Primary CompletionNov 2014
Study CompletionJul 2015
TodayJul 2026
First PostedJan 29, 2013
Enrollment StartJun 3, 2013
Primary CompletionNov 14, 2014
Study CompletionJul 21, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.4 years ago
Interventions
ATRIPLAdrug